Recruiting Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib NCT07633626 Conditions ALK-positive Non-small Cell Lung Cancer (NSCLC), Adenocarcinoma, Adenocarcinoma of Lung, +23 more Locations Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo CTIC — Bogotá, Colombia View Trial Details
Not Yet Recruiting Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study NCT06785584 Conditions ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC), MPR, +1 more Locations Fujian Medical University Union Hospital — Fuzhou, Fujian, China View Trial Details
Active, Not Recruiting Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms NCT05987956 Conditions ALK-positive Non-small Cell Lung Cancer (NSCLC) Locations Omnicure Clinical Research — Doral, Florida, United States Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701 — Rockville, Maryland, United States View Trial Details
